Clinical Trial Update: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin [Phase 4]

View source ↗

Summary

Phase 4 study assessing PEGASYS (peginterferon alfa-2a 40KD) plus ribavirin in patients with chronic hepatitis C previously treated with PEG-Intron and ribaviri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PEGASYS (peginterferon alfa-2a 40KD) (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2016-06-08